ALKS · Alkermes plc
$52.89
-4.23% last session
End-of-day data · updated 2026-07-28
Market cap
$9B
Enterprise value
$10B
Trailing P/E
58.6
Forward P/E
32.2
Dividend yield
—
Beta
0.29
Avg volume
2M
Employees
2K
2D change
—
5D change
-0.45%
10D change
0.02%
30D change
-4.27%
60D change
24.98%
MTD change
1.95%
YTD change
88.46%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ALKS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-28
Latest call per bank · past 12 months
Wells Fargo
Overweight$65.00
+22.9% vs priceBank of America
Underperform$38.00
-28.2% vs priceRBC Capital
Outperform$56.00
+5.9% vs priceUBS
Buy$48.00
-9.2% vs priceDeutsche Bank
Buy$45.00
-14.9% vs priceJP Morgan
Neutral$35.00
-33.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-28 | Piper Sandler | Reiterates | Overweight | $43.00 → $65.00 |
| 2026-07-20 | Stifel | Reiterates | Buy | $45.00 → $63.00 |
| 2026-07-13 | Needham | Maintains | Buy | $61.00 → $62.00 |
| 2026-07-02 | Mizuho | Maintains | Outperform | $53.00 → $65.00 |
| 2026-06-29 | Wells Fargo | Maintains | Overweight | $44.00 → $65.00 |
| 2026-06-29 | Bank of America | Downgrade | Neutral → Underperform | $0.00 → $38.00 |
| 2026-06-24 | Needham | Maintains | Buy | $54.00 → $61.00 |
| 2026-06-22 | TD Cowen | Maintains | Buy | $42.00 → $50.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 8.1% above the 50-day MA ($46.72).
- Price vs 200-day MA: Trading 43.8% above the 200-day MA ($35.13).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.61) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($26.13) and high ($55.22).
ALKS Price Chart
Loading chart for ALKS…
Fundamentals
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 11.9% YTD
HLN
Haleon plc
$44B -0.4% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.4% YTD
ZTS
Zoetis Inc.
$32B -37.9% YTD
UTHR
United Therapeutics Corporation
$26B 8.3% YTD
VTRS
Viatris Inc.
$21B 43.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 24.4% YTD
ELAN
Elanco Animal Health Incorporat
$13B 12.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.